跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 41,789 条关于
“EGFR exon 20 insertion-mutated NSCLC”
全部
41,789
临床试验
32,231
药物
1,397
机构
136
资讯
8,025
去年
FDA Reviewing Sunvozertinib for EGFR Exon 20 Insertion-Mutated NSCLC
3年前
FDA Grants Priority Review to Sunvozertinib for EGFR Exon 20 Insertion-Mutated NSCLC
去年
PALOMA-2 Study Confirms Efficacy of Subcutaneous Amivantamab in EGFR Exon 20 Insertion NSCLC
2年前
Novel Strategies Emerge to Optimize Treatment in EGFR-Mutant NSCLC
2年前
Zipalertinib Shows Promise in EGFR Exon 20-Mutated NSCLC After Amivantamab Failure
3天前
PAPILLON Final Analysis: RYBREVANT Plus Chemotherapy Delivers Longest Reported Median Overall Survival in EGFR Exon 20 Insertion NSCLC
3天前
PAPILLON Final Analysis: Amivantamab Plus Chemotherapy Delivers 34.3-Month Median OS in EGFR Exon 20 Insertion NSCLC
3天前
Zipalertinib Plus Chemotherapy Cuts Progression Risk 50% in First-Line EGFR Exon 20 Insertion NSCLC
9个月前
Scottish Medicines Consortium Approves Rybrevant Combination for First-Line EGFR Exon 20 Insertion NSCLC Treatment
4年前
Sunvozertinib Shows Promising 37.5% Response Rate in Phase I Trial for EGFR Exon 20 Insertion NSCLC
第 1 页，共 803 页
上一页
下一页
